These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26858935)

  • 1. Clinical Overview of MDM2/X-Targeted Therapies.
    Burgess A; Chia KM; Haupt S; Thomas D; Haupt Y; Lim E
    Front Oncol; 2016; 6():7. PubMed ID: 26858935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
    Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
    Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M; Barcherini V; Lopes EA; Santos MMM
    Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
    Qi SM; Cheng G; Cheng XD; Xu Z; Xu B; Zhang WD; Qin JJ
    Front Cell Dev Biol; 2020; 8():233. PubMed ID: 32300595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.
    Chopra H; Khan Z; Contreras J; Wang H; Sedrak A; Zhu Y
    Oncotarget; 2018 Jan; 9(5):6270-6281. PubMed ID: 29464071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological activation of wild-type p53 in the therapy of leukemia.
    Kojima K; Ishizawa J; Andreeff M
    Exp Hematol; 2016 Sep; 44(9):791-798. PubMed ID: 27327543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas.
    Touqan N; Diggle CP; Verghese ET; Perry S; Horgan K; Merchant W; Anwar R; Markham AF; Carr IM; Achuthan R
    BMC Clin Pathol; 2013 Dec; 13(1):32. PubMed ID: 24330579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K; Mane J; Friesen D; Tuszynski J
    J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
    Skalniak L; Surmiak E; Holak TA
    Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.